Clinical trials: 5-FU
Colorectal Cancer
Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients
The fluoropyrimidines 5-fluorouracil (5FU) and capecitabine (Cp) are among the most commonly used anticancer drugs. Still, there is much controversy about the correct dosing, and the fact that a minority of patients experience…
- Trial name
- FLOXTOX2 (NCT01641458)
- Testing
- 5FU and capecitabine (Xeloda®) dosing based on DPYD genotype, Therapeutic drug monitoring of 5FU
- Where
- 2 sites in Switzerland
- Volunteers
- 37 people
- Sponsor
- Cantonal Hospital of St. Gallen
Advanced or Metastatic Cholangiocellular Carcinoma and Bile Duct
Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct
To test the efficacy of a combination chemotherapy of imatinib and 5-FU in advanced or metastatic cholangiocellular carcinoma.
- Trial name
- NCT01153750
- Testing
- Glivec
- Where
- 8 sites in Germany
- Volunteers
- 44 people
- Sponsor
- University Hospital Dresden
Pancreatic Cancer
Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416507
- Testing
- fluorouracil, gemcitabine hydrochloride, liposomal cisplatin
- Volunteers
- 190 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Pancreatic Cancer, Adenocarcinoma
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer.
- Conditions
- Pancreatic Cancer, Adenocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT01383538
- Testing
- FOLFIRINOX, IPI-926
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Andrew Ko
Rectal Cancer
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer
The study is designed to test the hypothesis that the clinical complete response (CCR) rate of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy will increase after an adaptive-design…
- Trial name
- NCT04443543
- Testing
- Capecitabine (Xeloda) Pharmacogenetic Test Reagents, irinotecan, IMRT
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Fudan University
Colon Cancer, Rectal Cancer
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC).
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
- Trial name
- FRUITFUL (NCT07011576)
- Testing
- fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Docetaxel in Node Positive Adjuvant Breast Cancer
The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable…
- Trial name
- TAX316 (NCT00688740)
- Testing
- Docetaxel, 5-fluorouracil, Doxorubicin
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 1,491 people
- Sponsor
- Sanofi
Locally Advanced Gastric Carcinoma
Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell
Background Local advanced gastric carcinoma (LAGC) is suggested to be potentially cured by R0 resection, and neoadjuvant chemotherapy can increase the R0 resection rate but not enough.
- Trial name
- NCT02048540
- Testing
- Bevacizumab, docetaxel oxaliplatin 5-FU CF, Gastrectomy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Chinese PLA General Hospital
Colorectal Cancer
FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. Blood clots are a problem in patients with cancer. Blood clots are also a problem in patients receiving cancer drugs.
- Trial name
- NCT00323011
- Testing
- Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Southern California
Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma
Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)
The DeLOS II trial is a multicenter randomised phase II trial investigating a TP/5-Fluorouracil (TPF)-chemotherapy with or without cetuximab for Patients with only by laryngectomy operable carcinoma of the larynx/hypopharynx.
- Trial name
- DeLOS II (NCT00508664)
- Testing
- Radiation, Cetuximab, Docetaxel
- Where
- 27 sites in Austria, Germany
- Volunteers
- 180 people
- Sponsor
- ClinAssess
Hepatocellular Carcinoma
Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy
The purpose of this study is to determine the recommended dose of the combination therapy of sorafenib with hepatic arterial infusion of low dose cisplatin and fluorouracil on patients with advanced hepatocellular carcinoma…
- Trial name
- SILIUS (NCT00933816)
- Testing
- sorafenib, cisplatin, fluorouracil
- Where
- 3 sites in Japan
- Volunteers
- 37 people
- Sponsor
- Kindai University
Pancreatic Cancer
FOLFIRINOX + RT for Pancreatic Cancer
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of a therapy to learn whether the therapy works in treating a specific cancer.
- Trial name
- NCT01591733
- Testing
- FOLFIRINOX, Capecitabine, Short Course Radiation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Liver Metastasis Colon Cancer, Synchronous Neoplasm
Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer
This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including…
- Trial name
- NCT05362825
- Testing
- Neo-adjuvant Chemotherapy FOLFOXIRI Regimen, synchronous resection surgery
- Where
- Vietnam
- Volunteers
- 89 people
- Sponsor
- Cho Ray Hospital
Dacryocystorhinostomy, Hydroxybutyl Chitosan
Safety and Efficacy of Thermosensitive Hydroxybutyl Chitosan and 5-fluorouracil Assisted Endoscopic Dacryocystorhinostomy in the Treatment of Chronic Dacryocystitis
Endoscopic dacryocystorhinostomy (En-DCR) has the advantages of less surgical trauma, shorter time, less postoperative bleeding, faster recovery, and no skin scars.
- Conditions
- Dacryocystorhinostomy, Hydroxybutyl Chitosan, Fluorouracil, Chronic Dacryocystitis
- Trial name
- NCT06175676
- Testing
- Hydroxybutyl chitosan, 5-Fluorouracil, Gelatin Sponge Sheet
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Eye Hospital
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
The research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a…
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07059611
- Testing
- RP2, 5-Fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Rectal Cancer
Capecitabine in the Perioperative Treatment of Rectal Cancer
This study compares capecitabine with standard 5-FU in the perioperative treatment of locally advanced rectal cancer.
- Trial name
- Rektum-III (NCT01500993)
- Testing
- Capecitabine, 5-FU
- Where
- 14 sites in Germany
- Volunteers
- 401 people
- Sponsor
- Universitätsmedizin Mannheim
Metastatic Colorectal Cancer
Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer
This study is to assess the efficacy and safety of Endostar combined with mFOLFOX6 in untreated metastatic colorectal cancer patients, and to find the markers that may predict the efficacy.
- Trial name
- NCT01832948
- Testing
- Endostar, Oxaliplatin, Folinic acid
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer, Salvage Radiotherapy
Simultaneous Integrated Boost for Mediastinal Lymph Node Recurrence After Radical Surgery of Esophageal Cancer
Esophageal cancer (EC) ranks the seventh most diagnosed malignant tumor (572,000 new cases) and the sixth cancer-related mortality (509,000 deaths) worldwide in 2018.
- Conditions
- Esophageal Cancer, Salvage Radiotherapy, Dose-escalation, Mediastinal Lymph Node Recurrence
- Trial name
- NCT03990532
- Testing
- treatment group(phase I), treatment group (phase II)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Stage III Hepatocellular Cancer (CNLC Staging)
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
This is a prospective, one-arm, phase II clinical study of intravenous mFOLFOX6 plus Camrelizumab combined with apatinib for CNLC stage III hepatocellular carcinoma
- Trial name
- NCT05412589
- Testing
- mFOLFOX7+Camrelizumab+Apatinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Rectal Neoplasms, Drug Therapy
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
To evaluate the efficacy and safety of totally neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) followed by short-course radiation therapy and XELOX chemotherapy in the patients with locally advanced…
- Conditions
- Rectal Neoplasms, Drug Therapy, Radiation
- Trial name
- NCT03484221
- Testing
- FOLFOXIRI, Short-Course Radiation Therapy(5Gy*5), XELOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.